Search Results - "Liu, Si‐Yang"

An Enzyme‐Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis‐Based Synergistic Cancer Therapy by Xu, Yuzhi, Liu, Si‐Yang, Zeng, Leli, Ma, Hansu, Zhang, Yanfei, Yang, Huihui, Liu, Yuchen, Fang, Shuo, Zhao, Jing, Xu, Yunsheng, Ashby, Charles R., He, Yulong, Dai, Zong, Pan, Yihang

“…Cuproptosis, a newly identified form of regulated cell death that is copper‐dependent, offers great opportunities for exploring the use of copper‐based…”
Get full text

Emerging evidence and treatment paradigm of non-small cell lung cancer by Liu, Si-Yang Maggie, Zheng, Mei-Mei, Pan, Yi, Liu, Si-Yang, Li, Yangqiu, Wu, Yi-Long

“…Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical…”
Get full text

Electrochemical Exfoliation of Pillared‐Layer Metal–Organic Framework to Boost the Oxygen Evolution Reaction by Huang, Jin, Li, Yun, Huang, Rui‐Kang, He, Chun‐Ting, Gong, Li, Hu, Qiong, Wang, Lishi, Xu, Yan‐Tong, Tian, Xiao‐Yun, Liu, Si‐Yang, Ye, Zi‐Ming, Wang, Fuxin, Zhou, Dong‐Dong, Zhang, Wei‐Xiong, Zhang, Jie‐Peng

“…Two‐dimensional (2D) materials and ultrathin nanosheets are advantageous for elevating the catalysis performance and elucidating the catalysis mechanism of…”
Get full text

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma by Dong, Zhong-Yi, Zhong, Wen-Zhao, Zhang, Xu-Chao, Su, Jian, Xie, Zhi, Liu, Si-Yang, Tu, Hai-Yan, Chen, Hua-Jun, Sun, Yue-Li, Zhou, Qing, Yang, Jin-Ji, Yang, Xue-Ning, Lin, Jia-Xin, Yan, Hong-Hong, Zhai, Hao-Ran, Yan, Li-Xu, Liao, Ri-Qiang, Wu, Si-Pei, Wu, Yi-Long

“…Although clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and ligand (PD-L1) signaling in non-small cell lung cancer…”
Get full text

Ultrathin 2D Copper(I) 1,2,4‐Triazolate Coordination Polymer Nanosheets for Efficient and Selective Gene Silencing and Photodynamic Therapy by Liu, Si‐Yang, Xu, Yuzhi, Yang, Huihui, Liu, Liping, Zhao, Meiting, Yin, Wen, Xu, Yan‐Tong, Huang, Ying, Tan, Chaoliang, Dai, Zong, Zhang, Hua, Zhang, Jie‐Peng, Chen, Xiao‐Ming

“…Gene silencing holds promise for cancer therapeutics because of its potential to inhibit genes involved in tumor development. However, gene silencing is still…”
Get full text

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer by Zhang, Jia-Tao, Liu, Si-Yang, Gao, Wei, Liu, Si-Yang Maggie, Yan, Hong-Hong, Ji, Liyan, Chen, Yu, Gong, Yuhua, Lu, Hong-Lian, Lin, Jun-Tao, Yin, Kai, Jiang, Ben-Yuan, Nie, Qiang, Liao, Ri-Qiang, Dong, Song, Guan, Yanfang, Dai, Pingping, Zhang, Xu-Chao, Yang, Jin-Ji, Tu, Hai-Yan, Xia, Xuefeng, Yi, Xin, Zhou, Qing, Zhong, Wen-Zhao, Yang, Xue-Ning, Wu, Yi-Long

“…The efficacy and potential limitations of molecular residual disease (MRD) detection urgently need to be fully elucidated in a larger population of non-small…”
Get more information

Flexible Cuprous Triazolate Frameworks as Highly Stable and Efficient Electrocatalysts for CO2 Reduction with Tunable C2H4/CH4 Selectivity by Zhuo, Lin‐Ling, Chen, Pin, Zheng, Kai, Zhang, Xue‐Wen, Wu, Jun‐Xi, Lin, Duo‐Yu, Liu, Si‐Yang, Wang, Zhi‐Shuo, Liu, Jin‐Yu, Zhou, Dong‐Dong, Zhang, Jie‐Peng

“…Cu‐based metal–organic frameworks have attracted much attention for electrocatalytic CO2 reduction, but they are generally instable and difficult to control…”
Get full text

Targeted Therapy in Early Stage Non-small Cell Lung Cancer by Liu, Si-Yang, Liu, Si-Yang Maggie, Zhong, Wen-Zhao, Wu, Yi-Long

“…Opinion statement Tyrosine kinase inhibitors (TKIs) have dramatically improved tumor response rates and survival benefits in advanced oncogenic non-small-cell…”
Get full text

Isolation of Structurally Heterogeneous TCR‐CD3 Extracellular Vesicle Subpopulations Using Caliper Strategy by Yin, Wen, Chen, Haitian, Cai, Jianye, Huang, Xing, Zhang, Lang, Xu, Yuzhi, Zheng, Jun, Liu, Si‐Yang, Zou, Xiaoyong, Dai, Zong, Yang, Yang

“…Cells in different states can release diverse types of extracellular vesicles (EVs) that participate in intracellular communication or pathological processes…”
Get full text

Photoluminescent Metal–Organic Frameworks for Gas Sensing by Lin, Rui‐Biao, Liu, Si‐Yang, Ye, Jia‐Wen, Li, Xu‐Yu, Zhang, Jie‐Peng

“…Luminescence of porous coordination polymers (PCPs) or metal–organic frameworks (MOFs) is sensitive to the type and concentration of chemical species in the…”
Get full text

Perioperative targeted therapy for oncogene-driven NSCLC by Liu, Si-Yang, Zhang, Jia-Tao, Zeng, Kang-Hui, Wu, Yi-Long

“…•Targeted therapy has stepped into the perioperative treatment setting for oncogenic NSCLC.•The role of adjuvant chemotherapy, surrogate endpoints, and…”
Get full text

A smartphone-assisted “all-in-one” paper chip for one-pot noninvasive detection of salivary glucose level by Lin, Qian, Huang, Jiaqi, Zhang, Yiling, Chen, Miaomiao, Xu, Yuzhi, Zou, Xiaoyong, Liu, Si-Yang, Dai, Zong

“…[Display omitted] •The chromogenic paper chip was facilely prepared by one-pot synthesis.•The “all-in-one” strategy fundamentally improves the stability and…”
Get full text

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial by Zhong, Wen-Zhao, Wang, Qun, Mao, Wei-Min, Xu, Song-Tao, Wu, Lin, Wei, Yu-Cheng, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Yin, Rong, Yang, Fan, Ren, Sheng-Xiang, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yang, Jin-Ji, Yan, Hong-Hong, Yang, Xue-Ning, Liu, Si-Yang, Zhou, Qing, Wu, Yi-Long

“…ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved…”
Get full text

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes by Liu, Si-Yang, Bao, Hua, Wang, Qun, Mao, Wei-Min, Chen, Yedan, Tong, Xiaoling, Xu, Song-Tao, Wu, Lin, Wei, Yu-Cheng, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Yin, Rong, Yang, Fan, Ren, Sheng-Xiang, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yan, Hong-Hong, Dong, Song, Zhang, Xu-Chao, Su, Jian, Yang, Jin-Ji, Yang, Xue-Ning, Zhou, Qing, Wu, Xue, Shao, Yang, Zhong, Wen-Zhao, Wu, Yi-Long

“…The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR -mutant stage II–IIIA…”
Get full text

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer by Dong, Zhong-Yi, Zhang, Jia-Tao, Liu, Si-Yang, Su, Jian, Zhang, Chao, Xie, Zhi, Zhou, Qing, Tu, Hai-Yan, Xu, Chong-Rui, Yan, Li-Xu, Li, Yu-Fa, Zhong, Wen-Zhao, Wu, Yi-Long

“…Patients with EGFR mutations showed unfavorable response to programmed cell death-1 (PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet…”
Get full text

Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients by Pan, Yi, Zhang, Jia-Tao, Gao, Xuan, Chen, Zhi-Yong, Yan, Bingfa, Tan, Pei-Xin, Yang, Xiao-Rong, Gao, Wei, Gong, Yuhua, Tian, Zihan, Liu, Si-Yang Maggie, Lin, Hui, Sun, Hao, Huang, Jie, Liu, Si-Yang, Yan, Hong-Hong, Dong, Song, Xu, Chong-Rui, Chen, Hua-Jun, Wang, Zhen, Li, Pansong, Guan, Yanfang, Wang, Bin-Chao, Yang, Jin-Ji, Tu, Hai-Yan, Yang, Xue-Ning, Zhong, Wen-Zhao, Xia, Xuefeng, Yi, Xin, Zhou, Qing, Wu, Yi-Long

“…The value of circulating tumor DNA (ctDNA) during chemoradiotherapy (CRT) remains unclear but is critical for detecting molecular residual disease (MRD). In…”
Get full text

In Situ Enzyme Immobilization with Oxygen‐Sensitive Luminescent Metal–Organic Frameworks to Realize “All‐in‐One” Multifunctions by Xu, Yuzhi, Liu, Si‐Yang, Liu, Junling, Zhang, Li, Chen, Danping, Chen, Jun, Ma, Yingjun, Zhang, Jie‐Peng, Dai, Zong, Zou, Xiaoyong

“…Metal–organic frameworks (MOFs) for enzyme immobilization have already shown superior tunable and designable characteristics, however, their diverse responsive…”
Get full text

A Noble-Metal-Free Porous Coordination Framework with Exceptional Sensing Efficiency for Oxygen by Lin, Rui-Biao, Li, Fang, Liu, Si-Yang, Qi, Xiao-Lin, Zhang, Jie-Peng, Chen, Xiao-Ming

“…Light material: By virtue of the unique framework structure and very high oxygen permeability, a noble‐metal‐free, highly fluorescent, porous coordination…”
Get full text

Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004) by Liu, Si-Yang, Chen, Qixun, Zhou, Chengzhi, Zhang, Huizhong, Li, Wen, Chen, Jianhua, Hu, Jian, Wu, Lin, Chen, Qunqing, Dai, Qiangsheng, Shan, Jian-Zhen, Xu, Fei, Liu, Si-Yang Maggie, Wu, Yi-Long

“…Background Camrelizumab has shown encouraging efficacy in advanced non-small cell lung cancer (NSCLC), either as monotherapy or combined with chemotherapy…”
Get full text

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer by Liu, Si-Yang Maggie, Chen, Cunte, Zhang, Yi-Kai, Zhong, Wen-Zhao, Wu, Yi-Long, Liu, Si-Yang, Li, Yangqiu

“…ADJUVANT-CTONG1104 reported a favorable survival outcome from adjuvant gefitinib treatment over chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC)…”
Get full text